Skip to main content
Clinical Trials/KCT0000985
KCT0000985
Completed
未知

An open-label, randomized, single-dose crossover study to compare the pharmacokinetics after the administration of HCP1201 tablet 500/10 mg and coadministration of metformin SR 500 mg and rosuvastatin 10 mg in healthy volunteers

Hanmi Pharm0 sites72 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Hanmi Pharm
Enrollment
72
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
Male

Investigators

Sponsor
Hanmi Pharm

Eligibility Criteria

Inclusion Criteria

  • 1\) Healthy male volunteer, age 20\~55 years
  • 2\) The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2
  • 3\) Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial
  • 4\) Subject who has the ability and willingness to participate the whole period of trial

Exclusion Criteria

  • 1\) Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.
  • 2\) Glomerular filtration rate is under 60ml/min which is calculated by serum creatinine value.
  • 3\) Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a half times.
  • 4\) SBP: lower than 90mmHg or higher than 150mmHg, DBP: lower thatn 60mmHg or higher than 100mmHg
  • 5\) History of relevant drug allergies or clinically significant hypersensitivity reaction.
  • 6\) Subjects who judged ineligible by the investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials